Cited by 150Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesChild and Adolescent Psychosocial and Emotional Development

Effects of Long-Term Atomoxetine Treatment for Young Children With Attention-Deficit/Hyperactivity Disorder

KRATOCHVIL, CHRISTOPHER J., WILENS, TIMOTHY E., GREENHILL, LAURENCE L., GAO, HAITAO, BAKER, KURT D., FELDMAN, PETER D., GELOWITZ, DOUGLAS L.·2006·Journal of the American Academy of Child & Adolescent Psychiatry

Abstract

Objective The purpose of this 13-study (seven double-blind/placebo-controlled, six open-label) meta-analysis is to determine the effectiveness and tolerability of long-term atomoxetine treatment among young children with attention-deficit/hyperactivity disorder (ADHD).Method Data were pooled from 6- and 7-year-olds (N = 272) who met DSM-IV criteria for ADHD, received atomoxetine treatment, and were enrolled in clinical trials of > or =2 years. Of these, 97 subjects reached the 24-month time point, providing data for long-term trend analysis of safety and effectiveness.Results Effectiveness for most subjects was maintained over long-term treatment, as demonstrated by total scores and total T scores on the Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version, investigator administered and scored. During the 2-year period, 25.7% discontinued because of lack of effectiveness, but adverse events were clinically minor and transient, and only 4.0% of children discontinued because of an adverse event. Notable effects on growth were seen during early phases of the study, with attenuation occurring by the 2-year time point. Statistically significant increases in pulse and blood pressure and decreases in cardiac PR interval were seen, but no changes were deemed both statistically significant and clinically meaningful among any vital signs, electrocardiographic measures, or laboratory tests.Conclusion Long-term atomoxetine treatment appears generally well tolerated and effective in the treatment of young children with ADHD.

Integrity signals

Registry

Crossref · 10.1097/01.chi.0000222788.34229.68

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
KRATOCHVIL, C. J., WILENS, T. E., GREENHILL, L. L., GAO, H., BAKER, K. D., FELDMAN, P. D., & GELOWITZ, D. L.
Affiliations
Harvard University (US)
Corresponding author
KRATOCHVIL, CHRISTOPHER J.
Venue
Journal of the American Academy of Child & Adolescent Psychiatry
Publisher
Elsevier BV
Published
2006-08
Volume
45
Issue
8
Pages
919-927
ISSN
0890-8567 (ISSN-L)
OpenAlex
W1965946834
Cited by
150
References
37
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 9 · 2014: 9 · 2013: 10 · 2012: 6
FWCI
2.39
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
Keywords
atomoxetine, attention deficit hyperactivity disorder, young children, long-term treatment, treatment effectiveness, tolerability, adverse events, growth, blood pressure, pulse rate, ADHD Rating Scale-IV
MeSH terms
Atomoxetine Hydrochloride, Attention Deficit Disorder with Hyperactivity, Child, Female, Humans, Male, Propylamines, Time Factors, Adrenergic Uptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review